Umesh Gangadharmath

Dr. Umesh Gangadharmath is the VP of Operations and brings with him an extensive amount of radiochemistry and radiopharmaceutical experience both in academic and commercial settings. Umesh has designed and synthesized novel radiopharmaceuticals for use in positron emission tomography (PET) imaging of oncology, cardiology and neurological targets, including a marker for hypoxia (18F-HX4), apoptosis (18F-CP18) and markers for Tau (18F-T808/T807(AV1451)). He was an early adopter of ‘click chemistry’ as a tool to accelerate PET radiopharmaceutical development. Umesh has extensive experience in radiosynthesis process optimization, quality control and validation, technology transfer, site set-up and qualification, regulatory filling, FDA audit and responses. He has established PET tracer manufacturing sites globally (US, EU and Asia) to support PET imaging-based clinical trials. Dr. Gangadharmath has published several peer reviewed articles in PET and is an inventor on multiple radiopharmaceutical patents. He received his M.Sc and Ph.D in Inorganic chemistry from Karnatak University Dharwad, India in 2002 and was a former post-doctoral student at the University of California, Los Angeles in 2005. Umesh is a Participating member of the Editorial Advisory Board for Radiochemical Syntheses: Radiopharmaceuticals for Positron Emission Tomography (publisher: Wiley) and is currently serving as a member of United States Pharmacopeia (USP) Radioactive Drugs Expert Panel.